Wnt1 overexpression associated with tumor proliferation and a poor prognosis in non-small cell lung cancer patients

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 203-209

  Nakashima, Takashi ^a   Liu, Dage ^a   Nakano, Jun ^a   Ishikawa, Shinya ^a   Yokomise, Hiroyasu ^a   Ueno, Masaki ^a   Kadota, Kyuichi ^b   Huang, Cheng Long ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY   (Japan)

Author keywords

c Myc; Lung cancer; Prognosis; Proliferation; Wnt1

Indexed keywords

KI 67 ANTIGEN; MYC PROTEIN; WNT1 PROTEIN;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; CYTOPLASM; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; SQUAMOUS CELL CARCINOMA; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; UPREGULATION;

EID: 38749108492     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.203     Document Type: Article

References (40)

1. Cersosimo RJ: Lung cancer: a review. Am J Health Syst Pharm 59: 611-642, 2002.
2. Huang C, Liu D, Masuya D, Nakashima T, Kameyama K, Ishikawa S, Ueno M, Haba R and Yokomise H: Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 92: 1231-1239, 2005.
3. Weir B, Zhao X and Meyerson M: Somatic alterations in the human cancer genome. Cancer Cell 6: 433-438, 2004.
4. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y and Yasumoto K: Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg 115: 1007-1014, 1998.
5. Adachi M, Taki T, Konishi T, Huang C, Higashiyama M and Miyake M: Novel staging protocol for non-small-cell lung cancers according to MRP-1/CD9 and KAI1/CD82 gene expression. J Clin Oncol 16: 1397-1406, 1998.
6. Katoh M: Expression and regulation of WNT1 in human cancer: up-regulation of WNT1 by beta-estradiol in MCF-7 cells. Int J Oncol 22: 209-212, 2003.
7. Chen G, Shukeir N, Potti A, Sircar K, Aprikian A, Goltzman D and Rabbani SA: Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 101: 1345-1356, 2004.
8. Zhang WM, Lo Muzio L, Rubini C and Yan G: Effect of WNT-1 on beta-catenin expression and its relation to Ki-67 and tumor differentiation in oral squamous cell carcinoma. Oncol Rep 13: 1095-1099, 2005.
9. Huang C, Liu D, Nakano J, Ishikawa S, Kontani K, Yokomise H and Ueno M: Wnt5a expression is associated with the tumor proliferation and the stromal vascular endothelial growth factor - an expression in non-small-cell lung cancer. J Clin Oncol 23: 8765-8773, 2005.
10. Herzlinger D, Qiao J, Cohen D, Ramakrishna N and Brown AM: Induction of kidney epithelial morphogenesis by cells expressing Wnt-1. Dev Biol 166: 815-818, 1994.
11. Dale TC: Signal transduction by the Wnt family of ligands. Biochem J 329: 209-223, 1998.
12. Labbe E, Lock L, Letamendia A, Gorska AE, Gryfe R, Gallinger S, Moses HL and Attisano L: Transcriptional cooperation between the transforming growth factor-beta and Wnt pathways in mammary and intestinal tumorigenesis. Cancer Res 67: 75-84, 2007.
13. Huang C, Liu D, Masuya D, Kameyama K, Nakashima T, Yokomise H, Ueno M and Miyake M: MRP-1/CD9 gene transduction downregulates Wnt signal pathways. Oncogene 23: 7475-7483, 2004.
14. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B and Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 281: 1509-1512, 1998.
15. Scagliotti GV, Micela M, Gubetta L, Leonardo E, Cappia S, Borasio P and Pozzi E: Prognostic significance of Ki67 labelling in resected non small cell lung cancer. Eur J Cancer 29: 363-365, 1993.
16. 2+ pathways. Oncogene 18: 7860-7872, 1999.
17. Turashvili G, Bouchal J, Burkadze G and Kolar Z: Wnt signaling pathway in mammary gland development and carcinogenesis. Pathobiology 73: 213-223, 2006.
18. Mizushima T, Nakagawa H, Kamberov YG, Wilder EL, Klein PS and Rustgi AK: Wnt-1 but not epidermal growth factor induced β-catenin/T-cell factor-dependent transcription in esophageal cancer cells. Cancer Res 62: 277-282, 2002.
19. Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B and Clevers H: Constitutive transcriptional activation by a β-catenin-Tcf complex in APC-/- colon carcinoma. Science 275: 1784-1787, 1997.
20. Lo Muzio L, Pannone G, Staibano S, Mignogna MD, Grieco M, Ramires P, Romito AM, De Rosa G and Piattelli A: WNT-1 expression in basal cell carcinoma of head and neck. An immunohistochemical and confocal study with regard to the intracellular distribution of beta-catenin. Anticancer Res 22: 565-576, 2002.
21. Hirsch C, Campano LM, Wohrle S and Hecht A: Canonical Wnt signaling transiently stimulates proliferation and enhances neurogenesis in neonatal neural progenitor cultures. Exp Cell Res 313: 572-587, 2007.
22. Cappellen D, Schlange T, Bauer M, Maurer F and Hynes NE: Novel c-MYC target genes mediate differential effects on cell proliferation and migration. EMBO Rep 8: 70-76, 2007.
23. Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B and Jablons D: Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg 133: 733-737, 2007.
24. Obaya AJ, Mateyak MK and Sedivy JM: Mysterious liaisons: the relationship between c-Myc and the cell cycle. Oncogene 18: 2934-2941, 1999.
25. Dang CV, Resar LM, Emison E, Kim S, Li Q, Prescott JE, Wonsey D and Zeller K: Function of the c-Myc oncogenic transcription factor. Exp Cell Res 253: 63-77, 1999.
26. Zajac-Kaye M: Myc oncogene: a key component in cell cycle regulation and its implication for lung cancer. Lung Cancer 34: 543-546, 2001.
27. Akie K, Dosaka-Akita H, Murakami A and Kawakami Y: A combination treatment of c-myc antisense DNA with all-transretinoic acid inhibits cell proliferation by downregulating c-myc expression in small cell lung cancer. Antisense Nucleic Acid Drug Dev 10: 243-249, 2000.
28. D'Agnano I, Valentini A, Gatti G, Chersi A and Felsani A: Oligopeptides impairing the Myc-Max heterodimerization inhibit lung cancer cell proliferation by reducing Myc transcriptional activity. J Cell Physiol 210: 72-80, 2007.
29. Richardson GE and Johnson BE: The biology of lung cancer. Semin Oncol 20: 105-127, 1993.
30. Broers JL, Viallet J, Jensen SM, Pass H, Travis WD, Minna JD and Linnoila RI: Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am J Respir Cell Mol Biol 9: 33-43, 1993.
31. Volm M and Koomagi R: Prognostic relevance of c-Myc and caspase-3 for patients with non-small cell lung cancer. Oncol Rep 7: 95-98, 2000.
32. Geisler JP, Geisler HE, Manahan KJ, Miller GA, Wiemann MC, Zhou Z and Crabtree W: Nuclear and cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival. Int J Gynecol Cancer 14: 133-137, 2004.
33. Yang G, Timmie TL, Frolov A, Wheeler TM and Thompson TC: Combined c-Myc and caveolin- 1 expression in human prostate carcinoma predicts prostate carcinoma progression. Cancer 103: 1186-1194, 2005.
34. Kubokura H, Tenjin T, Akiyama H, Koizumi K, Nishimura H, Yamamoto M and Tanaka S. Relations of the c-myc gene and chromosme 8 in non-small cell lung cancer: analysis by fluorescence in situ hybridization. Ann Thorac Cardiovasc Surg 7: 197-203, 2001.
35. Bondi J, Bukholm G, Nesland JM and Bukholm IR: Expression of non-membranous beta-catenin and gamma-catenin, c-Myc and cyclin D1 in relation to patient outcome in human colon adenocarcinomas. APMIS 112: 49-56, 2004.
36. Ozaki S, Ikeda S, Ishizaki Y, Kurihara T, Tokumoto N, Iseki M, Arihiro K, Kataoka T, Okajima M and Asahara T: Alterations and correlations of the components in the Wnt signaling pathway and its target genes in breast cancer. Oncol Rep 14: 1437-1443, 2005.
37. Bienz M and Clevers H: Linking colorectal cancer to Wnt signaling. Cell 103: 311-320, 2000.
38. Ueda M, Gemmill RM, West J, Winn R, Sugita M, Tanaka N, Ueki M and Drabkin HA: Mutations of the beta- and gamma-catenin genes are uncommon in human lung, breast, kidney, cervical and ovarian carcinomas. Br J Cancer 85: 64-68, 2001.
39. 1-to S-phase cell-cycle regulators. Am J Pathol 161: 1619-1634, 2002.
40. Faivre EJ and Lange CA: Progesterone receptors upregulate Wnt-1 to induce epidermal growth factor receptor transactivation and c-Src-dependent sustained activation of Erk1/2 mitogen-activated protein kinase in breast cancer cells. Mol Cell Biol 27: 466-480, 2007.